Communiqués Biomark Diagnostics Inc.

Actions

20B

CA09073K1084

Temps Différé Deutsche Boerse AG Autres places de cotation 08:14:38 17/07/2024			Varia. 5j.	Varia. 1 janv.
0,124 ^EUR	0,00 %		-8,15 %	-15,65 %

29/02	Biomark Diagnostics Inc. publie ses résultats pour le troisième trimestre et les neuf mois clos le 31 décembre 2023	CI
28/02	BioMark Diagnostics Inc. s'associe à Rubix LS pour faire progresser le dépistage sanguin du cancer dans les communautés mal desservies	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research at 2024 GPEN Conference	15/07	NE
Biomark Diagnostics : Announces Warrant Extension and Granting of Options	06/05	PU
BioMark Announces Warrant Extension and Granting of Options	18/04	NE
BioMark to Advance Development of Cancer Treatment for Glioblastoma	09/04	NE
BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities	28/02	NE
Theresa Peterson Joins Biomark's Advisory Team	26/02	NE
BioMark Announces Closing of $1.9 Million Non-Brokered Private Placement	29/12	NE
BioMark Announces Recent New Patent Granted in Canada to Support Its Liquid Biopsy Based Legacy Assay	04/12	NE
BioMark Provides Second Quarter Operational Update and Announces Extension to Warrant Exercise Term	28/11	NE
BioMark Strengthens and Expands Its Strategic Advisory Team in Pursuit of Commercialization Initiatives	14/11	NE
BioMark Announces Financial Contribution from the City of Quebec to Support Commercialization Initiatives of Its Proprietary Lung Cancer Detection Test	07/11	NE
BioMark to Unveil Results of Its Early Breast Cancer Study at the Upcoming San Antonio Breast Cancer Symposium	24/10/23	NE
Biomark Diagnostics : Une Technologie d’ici Pour Mieux Diagnostiquer le Cancer du Poumon – Local Technology for Improved Lung Cancer Diagnosis	10/09/23	PU
BioMark Diagnostics : Dr. Maksymuik Presents at Prestigous ASCO Annual Meeting	13/06/23	PU
BioMark Unveils Significant Scientific Advancements from Its Leading Liquid Biopsy Technology at ASCO 2023 Annual Meeting	05/06/23	NE
BioMark Announces Update from Ongoing Clinical Trial Using Its Lung Cancer Liquid Biopsy Test as It Prepares for Commercial Launch	11/01/23	NE
BioMark Diagnostics : Form 7 Monthly Progress Report December 1 2022	09/01/23	PU
BioMark Diagnostics : Form 7 Monthly Progress Report November 1 2022	13/12/22	PU
BioMark Continues to Strengthen its Intellectual Property position With New Patent	22/06/22	AQ
BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer	30/11/21	NE

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Biomark Diagnostics Inc.

Actions

20B

CA09073K1084

Communiqués

Filtres